Claims for Patent: 9,284,280

Summary for Patent: 9,284,280

Title:	Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide
Abstract:	A method is provided in which Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide is administered as an active ingredient to a subject for the purpose of treating or preventing certain diseases, disorders, and symptoms, or for promoting angiogenesis or gene therapy. The Form-I crystal exhibits diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2.theta. when the spectrum is obtained by using Cu K.alpha. radiation: 9.4 degrees, 9.8 degrees, 17.2 degrees, and 19.4 degrees. The targeted diseases and disorders include transient ischemic attack, diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, connective tissue disease, reocclusion/restenosis after percutaneous transluminal coronary angioplasty, arteriosclerosis, thrombosis, hypertension, pulmonary hypertension, ischemic disorder, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, allergy, bronchial asthma, ulcer, pressure ulcer (bedsore), restenosis after coronary intervention, thrombocytopenia by dialysis, the diseases in which fibrosis of organs or tissues is involved, erectile dysfunction, inflammatory bowel disease, and gastritis.
Inventor(s):	Itou; Hideyuki (Kyoto, JP)
Assignee:	NIPPON SHINYAKU CO., LTD. (Kyoto, JP)
Application Number:	14/160,641
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,284,280
Patent Claims:	1. A method for treating diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, inflammatory bowel disease, or symptoms associated with spinal canal stenosis, comprising the step of administering, as an active ingredient to a subject, a crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2.theta.: 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu K.alpha. radiation. 2. The method according to claim 1, wherein the method is for treating peripheral circulatory disturbance. 3. The method according to claim 1, wherein the method is for treating chronic arterial occlusion. 4. The method according to claim 1, wherein the method is for treating intermittent claudication. 5. The method according to claim 1, wherein the method is for treating scleroderma. 6. The method according to claim 1, wherein the method is for treating pulmonary hypertension. 7. The method according to claim 1, wherein the method is for treating pulmonary fibrosis. 8. The method according to claim 1, wherein the method is for treating symptoms associated with spinal canal stenosis. 9. The method according to claim 1, wherein the method is for treating chronic renal failure.